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Undifferentiated embryonal sarcoma of the liver (USEL) is a rare malignant hepatic tumor with a poor prognosis
that is usually observed in children (aged 6 to10 years) and rarely seen in adults. We present a case of USEL in a
27-year-old woman with no previous history of the disease. Laboratory tests performed on admission showed that the
patient had mildly elevated levels of aspartate aminotransferase, alanine transaminase, alkaline phosphatase, lactate
dehydrogenase, and γ-glutamyl transpeptidase. The levels of viral hepatitis and tumor serum markers were all within
normal limits. Computed tomography showed a large mass involving the right lobe and the medial segment of the
liver. Right trisectionectomy was performed. Microscopically, the tumor was composed of pleomorphic and
polynuclear dyskaryotic cells in a myxoid stroma with focal eosinophilic globules and no clear differentiation to
muscle. Histological diagnosis showed undifferentiated embryonal sarcoma. Adjuvant therapy with cisplatin,
vincristine, doxorubicin, cyclophosphamide, and actinomycin D was initiated. We administered a high dose of
etoposide to extract the patient’s peripheral blood stem cells and performed radiation therapy and peripheral
blood stem cell transplantation. At 5-year follow-up, the patient was alive without any evidence of recurrence.
Here, we describe the clinical and histopathological features of USEL as well as the therapeutic options for USEL in
adults with this disease.
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Undifferentiated embryonal sarcoma of the liver (UESL)
is a rare and aggressive malignant tumor that is observed
predominantly in children, with a peak incidence in the
age group of 6 to 10 years [1]. UESL was differentiated
from other sarcomas by Stocker and Ishak in 1978.
Although UESL is generally seen in children, it can also
occur in adults. Thus, regardless of the patient’s age, it is
important to consider this entity in differential diagnosis
of large hepatic masses. UESL is a potentially treatable
tumor, and for this reason, timely pathological diagnosis
and multidisciplinary therapy is crucial to increase the
chances of long-term survival. However, the standard
multidisciplinary therapy for UESL is a matter of debate.
Therefore, cases that show long-term survival with
multidisciplinary therapy have great clinical significance.
In this report, we present our experience in treating a* Correspondence: ywsrw243@yahoo.co.jp
1Department of Gastroenterological Surgery I, Hokkaido University Graduate
School of Medicine, N15, W7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan
© 2012 Noguchi et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or27-year-old woman with UESL. The patient underwent
complete resection of the tumor and postoperative multi-
disciplinary therapy, the details of which are reported
below.Case Presentation
The patient was a 27-year-old Japanese woman who had
right hypochondrial pain and low-grade fever. She con-
sulted a local doctor when these symptoms aggravated.
Computed tomography (CT) and ultrasonography showed
a large hepatic tumor, and she was referred to our hospital
for further examination and treatment. She was healthy
and had no remarkable family history. Laboratory studies
showed a normal serum bilirubin level and elevated levels
of aspartate aminotransferase (AST) (42 U/L), alanine
transaminase (ALT) (48 U/L), alkaline phosphatase (ALP)
(660 U/L), lactate dehydrogenase (LDH) (398 U/L), and
γ-glutamyl transpeptidase γ-(GPT) (204 U/L). Tests for
serum viral hepatitis markers for hepatitis B and C yielded
negative results. The levels of tumor markers, includingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 The cut surface showing a grayish-red soft mass with
cystic degeneration, together with areas of hemorrhage and
necrosis.
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sence-II (PIVKA-II), carcinoembryonic antigen (CEA),
carbohydrate antigen (CA) 19–9, and cancer antigen 125
(CA125), were within normal limits. Abdominal CT
(Figure 1a, b, and c) revealed a well-defined low-density
large heterogenous mass (21× 19× 14 cm) in the right
liver segments. Enhanced CT revealed vessels, septa, and
variable degrees of cystic change in the tumor and the ab-
sence of a solid compartment and enhanced-effect around
the tumor. These findings indicated the possibility of
UESL or mesenchymal hamartoma. Since her right hypo-
chondrial pain worsened and the tumor enlarged rapidly,
we considered that it was most likely UESL on the basis of
the clinical symptoms, laboratory data, and CT findings.
Considering the rapid progressive nature of UESL, right
trisectionectomy was performed for both diagnosis and
treatment on the day after admission. The tumor weighed
3,370 g. The cut surface revealed a grayish-red soft mass
with cystic degeneration and areas of hemorrhage and
necrosis (Figure 2). On microscopic examination, the
tumor showed viscous, cystic, and grayish solid areas. The
viscous area was composed of pleomorphic and poly-
nuclear dyskaryotic cells in a myxoid stroma with focal
eosinophilic globules (Figure 3a and b). The lumen in the
cystic area had no epithelium. The grayish area was com-
posed of myxoid stroma and atypical bile ducts and hepatic
cord. Immunohistochemical analysis showed that the
tumor did not express α-smooth-muscle actin (α-SMA),
desmin, myoglobin, human hematopoietic progenitor cell
marker (CD34), cytokeratin 19 antibody (AE-1/AE-3),Figure 1 (a, b, and c) Abdominal computed tomography scan showin
heterogeneity in the right segments of the liver. This tumor had vess
phase; b, portal vein phase; and c, delayed phase).hepatocyte paraffin 1 (HEP-PAR 1), and AFP, but it
showed focal expression of Ki-67 (index 35 %) and mostly
expressed p53. The differentiation to muscle was not clear
in hematoxylin-eosin staining and other immunohisto-
chemical analyses. The surgical margin was free. On the
basis of these findings, a pathological diagnosis of UESL
was made. After surgery, the patient received two courses
of vincristine, adriamycin, cyclophosphamide, and actino-
mycin D (VADRCA)+ cisplatin (CDDP) in accordanceg a well-defined, low-density large mass (21×19×14 cm) with
els, septa, no enhanced-effect, and no solid compartment (a, early
Figure 3 (a and b) The viscous area showing pleomorphic and polynuclear dyskaryotic cells in a myxoid stroma with focal eosinophilic
globules (a, Hematoxylin-Eosin staining 4×, and b, 20×).
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coma study IRS-III [2] (Table 1). After the first course, the
patient underwent a high-dose etoposide regimen for ex-
traction of peripheral blood stem cells [3] (Table 2). During
the second course, she received additional radiation therapy
to remnant liver (Table 1). After the second course, she
received ranimustine, carboplatin, etoposide, cyclophospha-
mide (MCVC) therapy and underwent peripheral blood
stem cell transplantation [4] (Table 3). Follow-up imaging
studies, including a whole-body CT scan and positron
emission tomography (PET), showed no evidence of recur-
rence of the disease. She was healthy at the follow-up
examination conducted 60 months after the surgical
treatment.
Discussion
The incidence of UESL is highest in children between 6
and 10 years of age [1]. To the best of our knowledge, in
the past 50 years, less than 40 cases of UESL have been
reported in patients older than 20 years [5]. UESL
accounts for less than 1 % of all primary liver neoplasms
in adults, and there are no specific clinical features and
tumor makers. Furthermore, the results of imaging stud-
ies such as CT, ultrasonography, and magnetic resonance
imaging (MRI) are often inconclusive. Thus, UESL must
be considered during differential diagnosis of large liverTable 1 Adjuvant therapy: VADRCA+CDDP+RT
Drug (dose) 1 2 3 4 9 16 22 23 24 25 26 27 30 37
CDDP (90 mg/m2/day) # #
VCR (2 mg/m2/day) # # # # # #
ADM (30 mg/kg/day) # #
CTX (10 mg/kg/day) # # # # # #
ACT (0.015 mg/kg/day) # # # # #
Total course: two courses.
Radiation therapy with second course.
(20 Gray/10 fraction: day 6, 7, 9, 10, 13, 14, 16, 17, 20, 21).
ACT, actinomycin D; ADM, doxorubicin; CDDP, Cisplatin; CTX,
cyclophosphamide; VCR, vincristine.tumors in children and adults. The diagnosis of UESL
was delayed in some cases because the lesion presented
as a large cystic hepatic mass, suggesting a benign lesion
[6-12]. The prognosis of UESL is poor, but cases of long-
term survival have been reported. Multidisciplinary treat-
ment (chemotherapy and radiotherapy) has been used to
achieve superior and local control and disease-free sur-
vival in patients with UESL [13,14]. For example, 17 chil-
dren were reported to show long-term survival after
UESL [14]. In this report, four patients who received
complete resection followed by adjuvant chemotherapy
achieved complete remission over a follow-up period of
5 years to 10.9 years. One patient was treated with vin-
cristine, actinomycin, cyclophosphamide, and doxorubi-
cin (VACA), two were treated with vincristine,
actinomycin, ifosfamide, and doxorubicin (VAIA), and
one was treated with ifosfamide, vincristin, and actino-
mycin (VAIA-IVA). In this report, it was noted that the
response to chemotherapy was 62 %. In another report,
three children who received complete resection followed
by adjuvant chemotherapy of vincristine, actinomycin D,
and cyclophsphamide (VADRC-VAC) +CDDP for 1 year,
had a comparable prognosis with no evidence of the
disease over a follow-up period of 40 to 60 months [15].
In another report, adjuvant chemotherapy after complete
surgical resection of UESL showed significant thera-
peutic effects in adults [16]. In this report, all 14 patients
who underwent complete tumor resection followed by
adjuvant chemotherapy were alive after a median period
of 28.5 months (range, 6–204 months). On the other
hand, the 1-year and 2-year survival rates for all 14Table 2 Peripheral stem cell extraction
Schedule (day)
Peripheral stem cell extraction #
Drug (dose) 1 2 3
VP-16 (500 mg/m2/day) # # #
VP-16, etoposide.
Table 3 Peripheral stem cell transplantation
Schedule (day)
Peripheral stem cell transplantation #
Drug (dose) −8 −7 −6 −5 −4 −3 −2 −1
MCNU (200 mg/m2/day) # #
CBDCA(300 mg/m2/day) # # # #
VP-16 (500 mg/m2/day) # # #
CTX (50 mg/kg/day) # #
CBDCA, carboplatin; CTX, cyclophosphamide; MCNU, ranimustine; VP-16,
etoposide.
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receiving adjuvant chemotherapy was 53 %. Patients who
underwent a complete tumor resection followed by adju-
vant chemotherapy had significantly better survival rate
than patients who underwent only surgery. In five patients
who received incomplete surgical resection followed by
chemotherapy, one patient was alive without any evidence
of the disease after a follow-up of 6 months but all other
patients died of sarcoma-associated complications after a
median period of 12.5 months (range, 9–24 months). Three
patients with UESL, who underwent incomplete surgical
resection and received no postoperative chemotherapy, died
after a median period of 12 months (range, 5–67 months).
The difference in survival rates between these treatment
groups was found to be statistically insignificant. Complete
excision of the tumor seemed vital for cure. In addition,
adjuvant chemotherapy after complete resection seemed be
also important for cure. To our knowledge, only three adult
cases of UESL (aged> 20 years) with patient survival for
more than 60 months have been reported in literature
[9,16,17] (Table 4). Complete resections were performed in
two of these patients. In the third case, the UESL ruptured
during the resection. After the operation, the cancer
recurred and the patient underwent two more operations.
However, he died because of recurrences at 67.6 months
after the first liver resection [9]. In the other two cases of
complete resection, postoperative chemotherapy wasTable 4 Adjuvant therapy, recurrence and outcome of long-te
sarcoma
Reference Year Age Resection
margin
Adjuvant treatment
Grazi [9] 1996 25 Positive None
Alomogy [17] 2005 21 Negative I + ADM, Re-resectionI + ADM
Lenze [16] 2008 34 Negative None
Present 2011 27 Negative DDP+ VCR+ADM+ACTRT+
(VP-16, MCNU, CBDNU, CBD
ACT, actinomycin D; ADM, doxorubicin; CBDCA, carboplatin; CTX, cyclophosphamide
no evidence of disease; PBSCT, pheripheral blood stem cell transplantation; RT, radiperformed after complete resections. In one case, the pa-
tient had two lesions in the right and left liver. At first, she
received hepatic right trisegmentectomy and was treated
postoperatively with five cycles of intravenous ifosfamide
(2,500 mg/m2, days 1–3), doxorubicin (50 mg/m2, day 2),
and mensa (2,000 mg/m2, days 1–3). She also underwent
resection of the left-side lesion and received two additional
cycles of the chemotherapeutic regimen mentioned above.
Both the resection margins were free. At 71 months after
the second hepatic operation, she was healthy with no evi-
dence of disease [17]. In the other case, the patient under-
went an extended resection of the right liver lobe and
partial resection of the diaphragm. The resection margin
was free of tumor infiltration. She did not receive post-
operative chemotherapy, and the tumor recurred 4 months
later in the region of the former right liver lobe and the
pelvis. She was treated with eight courses of intravenous
carboplatin (at a dose of 150 mg/m2 on days 1–4) and eto-
poside (at a dose of 150 mg/m2 on days 1–4). After a gap of
4 weeks, she received chemotherapy with doxorubicin (at a
dose of 30 mg/m2 on days 1–2) and ifosfamide (at a dose of
3,000 mg/m2 on days 1–3). The recurring lesions had
reduced. Over a period of approximately 6 years, she
received no further chemotherapy or surgical treatment
and showed no evidence of recurrence [16]. No evidence of
the disease was seen after complete resection and adjuvant
chemotherapy in all three cases showing long-term survival;
however, all the adjuvant chemotherapy regimens were dif-
ferent. Hence, we concluded that complete resection and
adjuvant therapy were necessary for long-term survival, but
the regimens of postoperative standard chemotherapy and
radiation are a matter of debate. There are some reports
that long-term survival cases of UESL with successful
surgery, free margin and after conventional chemotherapy,
but one case showed local recurrence despite successful
surgery and adjuvant chemotherapy [16]. Although
radiotherapy might be overtreated, we performed radio-
therapy after obtaining the patient’s consent in this case.
The findings of the cases of adult UESL, including this
















; DDP, cisplatin; DOD, dead of disease; I, ifosfamide; MCNU, ranimustine, NED,
otherapy; VCR, vincritine; VP-16, Etoposide.
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In summary, it was important to achieve accurate and
early diagnosis of UESL and include it in the differential
diagnosis of large liver masses, regardless of the patient’s
age. UESL is an aggressive tumor, but a combination of
surgical, chemotherapeutic, and radiological treatment
may prolong the patient’s survival. We believe that
complete resection is a very important factor for ensuring
long-term survival.
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